Press Resease

Oral Proteins and Peptides Market by Drug Type (Linaclotide, Plecanatide, Calcitonin, Insulin, and Octreotide) and by Application (Gastric & Digestive Disorders, Bone Diseases, Diabetes, Hormonal Disorders, and Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 – 2024

Published Date: 13-Sep-2018 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-3360 Status : Published

Global oral proteins and peptides market expected to reach around USD 1671.8 million by 2024, growing at a CAGR of 12.3 % between 2018 and 2024. The peptide and protein therapeutics are an important class of medicines, which are administered through the oral route to treat different diseases, which include hormonal, gastric, and metabolic disorders.

Description

The report covers forecast and analysis for the oral proteins and peptides market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints for the oral proteins and peptides market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the oral proteins and peptides market on a global level.

In order to give the users of this report a comprehensive view of the oral proteins and peptides market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a customer and region segments which are benchmarked based on their market size, growth rate, and general attractiveness.

Global Oral Proteins and Peptides Market

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the market on the global and regional basis. 

The study provides a decisive view of the oral proteins and peptides market by segmenting the market based on customer and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2025.
 
By drug type, the global oral proteins and peptides market is divided into insulin, linaclotide, calcitonin, plecanatide, and octreotide. Among these products, insulin is expected to account for the largest share of the market. Linaclotide was the fastest growing segment in 2017 and is expected to grab the largest share of total revenue in the coming years.

By application segment, the global oral proteins and peptides market is divided into diabetes, bone diseases, hormonal disorders, gastric & digestive disorders, and others. Diabetes was the leading application segment accounting largest revenue share in 2016. 

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further divided into major countries including the U.S., Germany, France, the UK, China, Japan, India, and Brazil. This segmentation includes demand for oral proteins and peptides based on individual segment and applications in all the regions and countries.

Some of the key players in oral proteins and peptides market include Allergan Plc, Chiasma, Inc., Synthetic Biologics, Generex Biotechnology Corp., Proxima Concepts Limited (Diabetology Ltd.), Novo Nordisk A/S, and Tarsa Therapeutics Inc., Synergy Pharmaceuticals Inc., Sanofi S.A., Biocon Limited, F. Hoffmann-La Roche AG, AstraZeneca Plc, Inc., Hovione Limited, Novartis International AG, among others.

This report segments the global oral proteins and peptides market as follows:

Global Oral Proteins and Peptides Market: Drug Type Segment Analysis

  • Integrated Drug
  • Linaclotide
  • Plecanatide
  • Calcitonin
  • Insulin 
  • Octreotide 

Global Oral Proteins and Peptides Market: Application Segment Analysis

  • Gastric & Digestive Disorders
  • Bone Diseases
  • Diabetes 
  • Hormonal Disorders
  • Others

Global Oral Proteins and Peptides Market: Regional Segment Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Oral Proteins and Peptides Market, 2015 - 2025 (USD Billion)
    • 2.2. Global Oral Proteins and Peptides Market: Snapshot
  •  
  • Chapter 3. Oral Proteins and Peptides - Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Oral Proteins and Peptides Market drivers: Impact analysis
      • 3.2.2. Growing prevalence of chronic diseases
      • 3.2.3. The increasing emphasis of key players on research and development activities
    • 3.3. Market Restraints
      • 3.3.1. Lack of awareness among consumers
      • 3.3.2. Stringent regulation policies
      • 3.3.3. Contradictions on efficacy and efficiency of oral peptides are expected to hamper growth of market
    • 3.4. Opportunities
      • 3.4.1. Rising number of oral protein formulations is projected to offer lucrative opportunities in forecast period
      • 3.4.2. Untapped Markets
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Drug Type
      • 3.6.2. Market attractiveness analysis, by Application Type
      • 3.6.3. Market attractiveness analysis, by Regional segment
  •  
  • Chapter 4. Global Oral Proteins and Peptides Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Oral Proteins and Peptides market: company market share, 2017
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development, Regional Expansion
  •  
  • Chapter 5. Global Oral Proteins and Peptides Market - Drug Type Segment Analysis
    • 5.1. Global Oral Proteins and Peptides market: Drug Type overview
      • 5.1.1. Global Oral Proteins and Peptides market revenue share, by Drug Type, 2015 and 2025
      • 5.1.2. Global Oral Proteins and Peptides market revenue share, by Linaclotide, 2015 - 2025
      • 5.1.3. Global Oral Proteins and Peptides market revenue share, by Plecanatide, 2015 - 2025
      • 5.1.4. Global Oral Proteins and Peptides market revenue share, by Calcitonin, 2015 - 2025
      • 5.1.5. Global Oral Proteins and Peptides market revenue share, by Insulin, 2015 - 2025
      • 5.1.6. Global Oral Proteins and Peptides market revenue share, by Octreotide, 2015 - 2025
  •  
  • Chapter 6. Global Oral Proteins and Peptides Market - Application Segment Analysis
    • 6.1. Global Oral Proteins and Peptides Market: Application overview
      • 6.1.1. Global Oral Proteins and Peptides market revenue share, Application, 2015 and 2025
      • 6.1.2. Global Oral Proteins and Peptides market for Gastric & Digestive Disorders, 2015 - 2025(USD Billion)
      • 6.1.3. Global Oral Proteins and Peptides market for Bone Diseases, 2015 - 2025(USD Billion)
      • 6.1.4. Global Oral Proteins and Peptides market for Diabetes, 2015 - 2025(USD Billion)
      • 6.1.5. Global Oral Proteins and Peptides market for Hormonal Disorders, 2015 - 2025(USD Billion)
      • 6.1.6. Global Oral Proteins and Peptides market for Others, 2015 - 2025(USD Billion)
  •  
  • Chapter 7. Global Oral Proteins and Peptides Market - Regional Segment Analysis
    • 7.1. Global Oral Proteins and Peptides market: Regional overview
      • 7.1.1. Global Oral Proteins and Peptides market revenue share, by region, 2015 and 2025
    • 7.2. North America
      • 7.2.1. North America Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
      • 7.2.2. North America Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
      • 7.2.3. U.S.
        • 7.2.3.1. U.S. Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
        • 7.2.3.2. U.S. Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
    • 7.3. Europe
      • 7.3.1. Europe Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
      • 7.3.2. Europe Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
      • 7.3.3. U.K.
        • 7.3.3.1. U.K. Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
        • 7.3.3.2. U.K. Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
      • 7.3.4. Germany
        • 7.3.4.1. Germany Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
        • 7.3.4.2. Germany Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
      • 7.3.5. France
        • 7.3.5.1. France Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
        • 7.3.5.2. France Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
      • 7.4.2. Asia Pacific Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
      • 7.4.3. China
        • 7.4.3.1. China Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
        • 7.4.3.2. China Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
      • 7.4.4. Japan
        • 7.4.4.1. Japan Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
        • 7.4.4.2. Japan Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
      • 7.4.5. India
        • 7.4.5.1. India Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
        • 7.4.5.2. India Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
    • 7.5. Latin America
      • 7.5.1. Latin America Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
      • 7.5.2. Latin America Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
      • 7.5.3. Brazil
        • 7.5.3.1. Brazil Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
        • 7.5.3.2. Brazil Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
    • 7.6. Middle East and Africa
      • 7.6.1. Middle East and Africa Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
      • 7.6.2. Middle East and Africa Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
  •  
  • Chapter 8. Company Profile
    • 8.1. Allergan plc
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Therapy portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. Sanofi S.A.
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Therapy portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. F. Hoffmann-La Roche AG
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Therapy portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. AstraZeneca Plc.
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Therapy portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
    • 8.5. Proxima Concepts Limited
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Therapy portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Tarsa Therapeutics Inc
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Therapy portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. Merge Healthcare Inc
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Therapy portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
    • 8.8. Chiasma, Inc.
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Therapy portfolio
      • 8.8.4. Business strategy
      • 8.8.5. Recent developments
    • 8.9. Synthetic Biologics
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Therapy portfolio
      • 8.9.4. Business strategy
      • 8.9.5. Recent developments
    • 8.10. Generex Biotechnology Corp.
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Therapy portfolio
      • 8.10.4. Business strategy
      • 8.10.5. Recent developments

Methodology

Free Analysis

Proteins and peptides are an important class of biological substances. Polypeptide hormones like insulin are used in treating various diseases. Proteins and peptides enhance successful delivery of the drug to the desired site of action. Many proteins and peptides possess biological activity that makes them potent therapeutics. These potent peptides and proteins are designed and engineered in the lab to treat a variety of diseases that are administered orally and are termed as oral protein and peptide-based drugs.

Growing advancements in the field of biotechnology have resulted in the development of many novel therapeutic drugs. Among them, oral peptide & proteins have attracted considerable attention in the industry. Oral protein and peptides are widely being used in treating several diseases due to their high potency and specificity. Spurring demand for oral proteins and peptides in the treatment of chronic conditions such as cancer, hepatitis, diabetes, rheumatoid arthritis, and leukemia is driving the growth of global oral proteins and peptides market. Increasing the focus of key players on oral peptide drug discovery and ongoing research activities in active protein production is anticipated to encourage the growth of global oral proteins and peptides market in the coming years. In addition, the rising prevalence of chronic disorders, including diabetes, cancer, and other potent diseases are boosting the demand for oral proteins and peptides. Furthermore, the presence of large untapped market in emerging countries, consumers’ growing shift towards high-quality health care, and demand for effective drugs and technology are boosting the global oral protein and peptide market.

Global Oral Proteins and Peptides Market

However, high drug manufacturing cost and large capital investment required for research and development activities of oral peptide drug may hinder the growth of this market. On the other hand, untapped market in developing countries, growing technological advancements in the development of new drugs, drugs under pipeline and clinical trial are expected to generate lucrative opportunities in the oral protein and peptides market in the forecast period.

By drug type, the global oral proteins and peptides market is divided into insulin, linaclotide, calcitonin, plecanatide, and octreotide. Among these products, insulin is expected to account for the largest share of the market. Linaclotide was the fastest growing segment in 2017 and is expected to grab a large share of total revenue in the coming years.

By application segment, the global oral proteins and peptides market is divided into diabetes, bone diseases, hormonal disorders, gastric & digestive disorder, and other. Diabetes was the leading application segment accounting for the largest revenue share in 2017. The outsized share of diabetes segment is primarily accredited to the high acceptance of oral insulin in diabetic population and relative increase in the prevalence of diabetes. The bone disease segment is expected to grow at the highest CAGR during the forecast period.

Based on geography, global oral proteins and peptides market is divided into five regions, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is expected to remain the dominant region in terms of revenue generation over the forecast period. Europe was the second largest market followed by the Asia Pacific. The Asia Pacific was the fastest growing market with the highest year on year growth rate. The Middle East and Africa and Latin America are expected to experience slow growth in the oral proteins and peptides market in the years to come. 

 Some of the key players in oral proteins and peptides market include Allergan Plc, Chiasma, Inc., Synthetic Biologics, Generex Biotechnology Corp., Proxima Concepts Limited (Diabetology Ltd.), Novo Nordisk A/S, and Tarsa Therapeutics Inc., Synergy Pharmaceuticals Inc., Sanofi S.A., Biocon Limited, F. Hoffmann-La Roche AG, AstraZeneca Plc., Hovione Limited, Novartis International AG, among others.

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com